Research On The Problem Of Commercial Bribery In Pharmaceutical Products Field

Hospital Pharmaceutical Products Commercial bribery refers to the behavior that in the activities of procurement or use of pharmaceutical products such as pharmaceuticals, medical devices, and medical materials, the national staff, non-national staff and medical personnel in hospitals, take advantage of his position to obtain the seller’s property, or illegally accept the seller’s property to seek interests for the seller.Hospital Pharmaceutical Products Commercial bribery is a special form of commercial bribery. It has the general characteristics of commercial bribery; meanwhile, it has its own peculiarities in terms of behavior subject, forms, and harmful consequences. As early as 2006, in the first commercial bribery special activities of the central deployment, medical and health fields had already been included one of the key points. Subsequently, the former Ministry of Health, the State Administration of TCM, the Supreme Court, the Supreme People’s Procuratorate and the State Health Planning Commission have issued documents jointly or separately to guide and carry out governance of commercial bribery, and have achieved some effectiveness. But in recent years, Hospital Pharmaceutical Products Commercial bribery such as the case of Glaxo Smith Kline occurred frequently, and even in some hospitals because of the commercial bribery the collapse of corruption occurs which indicating that hospital medicine commercial bribery situation is still very grim.The article contents 5 chapters. Chapter 1 introduces the background and significance of the article. Chapter 2 explains the main links and manifestations that Hospital Pharmaceutical Products Commercial bribery occurred, adding actual cases of commercial bribery in the pharmaceutical industry to analyze. Chapter 3 summarizes and analyzes the phenomena of Hospital Pharmaceutical Products Commercial bribery. Chapter 4 presents the governance dilemma of Hospital Pharmaceutical Products Commercial bribery, and analyzes the causes. Chapter 5, proposes systematic comprehensive governance model of a combination of measures.